• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

    10/17/23 8:12:51 AM ET
    $AGBA
    $AHG
    $AMAM
    $ATHX
    Investment Managers
    Finance
    Real Estate
    Real Estate
    Get the next $AGBA alert in real time by email

    Gainers

    • SciSparc Ltd. (NASDAQ:SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price Notification.
    • WiSA Technologies, Inc. (NASDAQ:WISA) shares rose 76.4% to $0.4380 in pre-market trading after falling 40% on Monday. WiSA Technologies announced the pricing of a $4.8 million public offering of Series B convertible redeemable preferred stock and warrants.
    • Athersys, Inc. (NASDAQ:ATHX) shares gained 51.5% to $0.1487 in pre-market trading. Athersys extended near-term liquidity with proceeds from warrant inducement and a global ARDS license with Healios to explore strategic alternatives.
    • Aurora Mobile Limited (NASDAQ:JG) shares climbed 50.8% to $0.2005 in pre-market trading after gaining 8% on Monday.
    • ZW Data Action Technologies Inc. (NASDAQ:CNET) rose 30.8% to $1.23 in pre-market trading after declining 13% on Monday.
    • Meiwu Technology Company Limited (NASDAQ:WNW) shares rose 30.4% to $0.12 in pre-market trading after falling 4% on Monday.
    • Jaguar Health, Inc. (NASDAQ:JAGX) gained 13.5% to $0.4085 in pre-market trading after gaining more than 12% on Monday.
    • Vistagen Therapeutics, Inc. (NASDAQ:VTGN) shares rose 12.6% to $3.57 in pre-market trading after a 13G filing showed Citadel Advisors LLC reported a 5.6% stake in the company.
    • AGBA Group Holding Limited (NASDAQ:AGBA) rose 12.2% to $0.55 in pre-market trading.
    • Akso Health Group (NASDAQ:AHG) shares jumped 8.6% to $2.01 in pre-market trading. Akso Health Group recently regained compliance with Nasdaq's Minimum Bid Price Requirement.

    Losers

    • Nuvve Holding Corp. (NASDAQ:NVVE) dipped 33.5% to $0.2599 in pre-market trading after gaining over 9% on Monday.
    • NetScout Systems, Inc. (NASDAQ:NTCT) shares fell 23% to $21.24 in pre-market trading after the company reported weak preliminary results for the second quarter and lowered its FY24 guidance.
    • Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) shares fell 18.6% to $0.4547 in pre-market trading, after jumping 16% on Monday.
    • MingZhu Logistics Holdings Limited (NASDAQ:YGMZ) shares fell 14.5% to $0.5731 in pre-market trading after jumping around 38% on Monday.
    • Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) fell 13.5% to $1.90 in pre-market trading after gaining 11% on Monday.
    • Ambrx Biopharma Inc. (NASDAQ:AMAM) fell 13.4% to $9.90 in pre-market trading after declining 19% on Monday. Ambrx Biopharma announced that two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic castration-resistant prostate cancer (mCRPC) were made available as part of the 2023 European Society of Medical Oncology Congress 2023 meeting.
    • 22nd Century Group, Inc. (NASDAQ:XXII) shares fell 11.9% to $0.4840 in pre-market trading after reporting a proposed public offering.
    • XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) fell 11.8% to $0.7528 in pre-market after dipping around 15% on Monday.
    • NuCana plc (NASDAQ:NCNA) shares fell 11.7% to $0.50 in pre-market trading after declining around 12% on Monday. NuCana presented data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023.
    • Avinger, Inc. (NASDAQ:AVGR) shares fell 11.2% to $5.71 in pre-market trading, after gaining over 21% on Monday.

    Now Read This: Investor Fear Eases Ahead Of Big Earnings

    Get the next $AGBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGBA
    $AHG
    $AMAM
    $ATHX

    CompanyDatePrice TargetRatingAnalyst
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    NetScout Systems Inc.
    $NTCT
    8/26/2025$33.00Buy
    B. Riley Securities
    NuCana plc
    $NCNA
    8/30/2024Outperform → Mkt Perform
    William Blair
    Rani Therapeutics Holdings Inc.
    $RANI
    8/2/2024$17.00Outperform
    Oppenheimer
    Rani Therapeutics Holdings Inc.
    $RANI
    6/14/2024$15.00Buy
    Maxim Group
    More analyst ratings

    $AGBA
    $AHG
    $AMAM
    $ATHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Maxim Group

    Maxim Group downgraded VistaGen from Buy to Hold

    12/17/25 12:23:57 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by William Blair

    William Blair downgraded VistaGen from Outperform to Mkt Perform

    12/17/25 11:34:15 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AHG
    $AMAM
    $ATHX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Imran Mir A bought $1,260,417 worth of shares (2,083,334 units at $0.60) (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/27/25 7:24:25 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yorke Justin W bought $9,889 worth of shares (12,400 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/31/25 5:06:27 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ng George K bought $69,542 worth of shares (87,200 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/29/25 5:05:00 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AHG
    $AMAM
    $ATHX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aurora Mobile Debuts Modellix: A Unified Gateway for Next-Gen AI Media Generation

    SINGAPORE, April 09, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ:JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services, today announced the official launch of Modellix.ai, a unified multimodal AI platform that provides a seamless, standardized bridge to global elite image and video models, transforming fragmented AI capabilities into scalable business innovation. (Image from Modellix.ai) Solving the Fragmentation Crisis in Generative AIAs generative AI adoption continues to accelerate, businesses and developers increasingly rely on multiple model providers to support image generation, video generation, image editing

    4/9/26 7:00:00 AM ET
    $JG
    Computer Software: Programming Data Processing
    Technology

    Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

    SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Dr. Sara Kenkare-Mitra as a Strategic Advisor. Dr. Kenkare-Mitra brings nearly three decades of experience in biologics and small molecule drug discovery and development, with a proven track record of global regulatory approvals and commercial launches across oncology, immunology, neurodegeneration, ophthalmology, and respiratory diseases. "Sara is a highly accomplished leader and respected drug developer, and we are thrilled to we

    4/9/26 7:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

    Company to Pursue Additional PMTA Submissions, Building on Its Status as the Only Holder of an FDA-Authorized Low Nicotine Combustible Cigarette Branded as VLN® Products Expanded PMTA Portfolio and Licensing Strategy Designed to Address Wider Consumer Preference and Unlock Further Retail Penetration Opportunities MOCKSVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced an update on the advancement of a 100mm VLN® reduced nicotine content cigarette. The Company's proprietary reduced nicotine technology is designed to serve adult smokers who w

    4/7/26 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AGBA
    $AHG
    $AMAM
    $ATHX
    SEC Filings

    View All

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    4/13/26 5:27:55 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by 22nd Century Group Inc.

    EFFECT - 22nd Century Group, Inc. (0001347858) (Filer)

    4/13/26 12:15:24 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by 22nd Century Group Inc.

    424B5 - 22nd Century Group, Inc. (0001347858) (Filer)

    4/10/26 4:35:13 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AGBA
    $AHG
    $AMAM
    $ATHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tressler Nick B.

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    4/9/26 8:43:16 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Singh Shawn

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    4/9/26 8:41:53 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Prince Joshua S.

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    4/9/26 8:40:22 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AHG
    $AMAM
    $ATHX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AGBA
    $AHG
    $AMAM
    $ATHX
    Leadership Updates

    Live Leadership Updates

    View All

    Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

    SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Dr. Sara Kenkare-Mitra as a Strategic Advisor. Dr. Kenkare-Mitra brings nearly three decades of experience in biologics and small molecule drug discovery and development, with a proven track record of global regulatory approvals and commercial launches across oncology, immunology, neurodegeneration, ophthalmology, and respiratory diseases. "Sara is a highly accomplished leader and respected drug developer, and we are thrilled to we

    4/9/26 7:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

    SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy. Mr. Høiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease. "Jesper is a highly respected leader with a rare combination of strategic insight and deep commercial experience, and we are thrilled to welcome him as Head of Strategy," said Talat Imr

    3/25/26 4:53:16 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AHG
    $AMAM
    $ATHX
    Financials

    Live finance-specific insights

    View All

    Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

    - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – - Initiated Phase 1 Study of RT-114 RaniPill® for the treatment of obesity in collaboration with ProGen

    3/26/26 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvve to Provide Fourth Quarter Ended December 31, 2025, Financial Update

    Investor Conference Call to be Held Tuesday, March 31, 2026, at 5:00 PM Eastern Time (2:00 PM PT) Nuvve Holding Corp. ("Nuvve") (NASDAQ:NVVE), a global leader in grid modernization and vehicle-to-grid (V2G) technology, will provide Fourth quarter ended December 31, 2025, update on Tuesday, March 31, 2026. Conference Call Details Nuvve will hold a conference call to review its financial results for the fourth quarter ended December 31, 2025, along with other company developments at 5:00 PM Eastern Time (2:00 PM PT), Tuesday, March 31, 2026. To participate in the call, please dial (888) 349-0097 or (412) 902-4245; Passcode: 7091129, or register for and listen via a live webcast, which

    3/26/26 8:00:00 AM ET
    $NVVE
    Electrical Products
    Industrials

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AGBA
    $AHG
    $AMAM
    $ATHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by WiSA Technologies Inc.

    SC 13G - WISA TECHNOLOGIES, INC. (0001682149) (Subject)

    11/14/24 5:27:55 PM ET
    $WISA
    Semiconductors
    Technology